Population pharmacokinetics and maximum a posteriori probability Bayesian estimator of abacavir: Application of individualized therapy in HIV-infected infants and toddlers

British Journal of Clinical Pharmacology

Volumn 73, Issue 4, 2012, Pages 641-650

  Zhao, Wei ^a,b   Cella, Massimo ^c   Della Pasqua, Oscar ^c,d   Burger, David ^e,f   Jacqz Aigrain, Evelyne ^a,b   Aboulker, J P ^v   Brothers, C ^v   Burger, D ^v   Compagnucci, A ^v   Giaquinto, C ^k,v   Gibb, D M ^v   Jacqz Aigrain, E ^v   Snowdon, W ^v   Firtion, G ^g   Boudjoudi, N ^g   Guerin, C ^g   Krivine, A ^g   Faye, A ^a   Damond, F ^a   Awaida, L ^a   Popon, M ^a   Wang, Y ^a   Thourer, F ^a   Floch, C ^h   Mazy, F ^h   Wintergerst, U ⁱ   Notheis, G ⁱ   Gunther G ^j   Rampon, O ^k   Zanchetta, M ^k   de Rossi, A ^k   Ramos Amador, J T ^l   Garcia Bermejo, I ^l   Molina, T ^l   Gonzalez Tome M I ^m   Delgado Garcia, R ^m   Ferrari, J M ^m   Pineiro, R ^m   Navarro Gomez, M L ⁿ   Sanjurjo Saez, M ⁿ   Jimenez, J L ⁿ   Lyall, H ^o   Hamadache, D ^o   Tudor Williams, G ^o   Foster, C ^o   Hanley, C ^o   Walsh, C ^o   Kaye, S ^o   Patel, D ^o   Welch, S ^p   Dawson, Y ^p   Scott, S ^p   Smit, E ^p   Atherton, C ^p   Shah, N ^p   Berry, A ^p   Gandhi, K ^p   Jones, R ^q   Blahut, M ^q   Day, L ^q   Smith, R ^q   Smith, F ^q   Morgan, R ^q   Lewis, P ^r   Daglish, J ^r   Stinson, J ^r   McMaster, P ^s   Jones, E ^s   Menson, E ^t   Cross, R ^t   Pillay, D ^u   Grant, P ^u   Kirk, S ^u   more..

^a HÔPITAL ROBERT DEBRÉ   (France)

^b INSERM   (France)

^c LEIDEN UNIVERSITY   (Netherlands)

^d GLAXOSMITHKLINE   (United Kingdom)

^e RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^f RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^g Port Royal Hospital   (France)

^h HÔPITAL LOUIS MOURIER   (France)

ⁱ Universitäts Kinderkliniken   (Germany)

^j OTTO VON GUERICKE UNIVERSITY   (Germany)

^k UNIVERSITY OF PADOVA   (Italy)

^l HOSPITAL UNIVERSITARIO DE GETAFE   (Spain)

^m HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

ⁿ HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^o IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^p BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

^q WEXHAM PARK HOSPITAL   (United Kingdom)

^r UNIVERSITY HOSPITALS COVENTRY AND WARWICKSHIRE NHS TRUST   (United Kingdom)

^s UNIVERSITY HOSPITAL OF NORTH STAFFORDSHIRE   (United Kingdom)

^t ST THOMAS HOSPITAL   (United Kingdom)

^u ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^v College Medical School ^*

more..

Author keywords

Abacavir; Human immunodeficiency virus; Maximum a posteriori probability Bayesian estimator; Paediatrics; Population pharmacokinetics

Indexed keywords

ABACAVIR;

AREA UNDER THE CURVE; ARTICLE; BAYES THEOREM; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; MALE; PREDICTION; PRESCHOOL CHILD; PRIORITY JOURNAL; PROBABILITY;

ANTI-HIV AGENTS; AREA UNDER CURVE; BAYES THEOREM; BODY WEIGHT; CHILD, PRESCHOOL; DIDEOXYNUCLEOSIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DOSAGE CALCULATIONS; FEMALE; HIV INFECTIONS; HUMANS; INFANT; MALE; MODELS, BIOLOGICAL;

EID: 84863229264     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2011.04121.x     Document Type: Article

References (31)

1. PENTA Steering Committee, Welch S, Sharland M, Lyall EG, Tudor-Williams G, Niehues T, Wintergerst U, Bunupuradah T, Hainaut M, Della Negra M, Pena MJ, Amador JT, Gattinara GC, Compagnucci A, Faye A, Giaquinto C, Gibb DM, Gandhi K, Forcat S, Buckberry K, Harper L, Königs C, Patel D, Bastiaans D. PENTA 2009 guidelines for the use of antiretroviral therapy in paediatric HIV-1 infection. HIV Med 2009; 10: 591-613.
2. McDowell JA, Chittick GE, Ravitch JR, Polk RE, Kerkering TM, Stein DS. Pharmacokinetics of [(14)C] abacavir, a human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitor, administered in a single oral dose to HIV-1-infected adults: a mass balance study. Antimicrob Agents Chemother 1999; 43: 2855-61.
3. Yuen GJ, Weller S, Pakes GE. A review of the pharmacokinetics of abacavir. Clin Pharmacokinet 2008; 47: 351-71.
4. Faletto MB, Miller WH, Garvey EP, St Clair MH, Daluge SM, Good SS. Unique intracellular activation of the potent anti-human immunodeficiency virus agent 1592U89. Antimicrob Agents Chemother 1997; 41: 1099-107.
5. Neely M, Jelliffe R. Practical therapeutic drug management in HIV-infected patients: use of population pharmacokinetic models supplemented by individualized Bayesian dose optimization. J Clin Pharmacol 2008; 48: 1081-91.
6. Fletcher CV, Anderson PL, Kakuda TN, Schacker TW, Henry K, Gross CR, Brundage RC. Concentration-controlled compared with conventional antiretroviral therapy for HIV infection. AIDS 2002; 16: 551-60.
7. Acosta E, Gerber J. Position paper on therapeutic drug monitoring of antiretroviral agents. AIDS Res Hum Retroviruses 2002; 18: 825-34.
8. Fraaij PL, Rakhmanina N, Burger DM, de Groot R. Therapeutic drug monitoring in children with HIV/AIDS. Ther Drug Monit 2004; 26: 122-6.
9. Weller S, Radomski KM, Lou Y, Stein DS. Population pharmacokinetics and pharmacodynamic modeling of abacavir (1592U89) from a dose-ranging, double-blind, randomized monotherapy trial with human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother 2000; 44: 2052-60.
10. Cella M, Gorter de Vries F, Burger D, Danhof M, Della Pasqua O. A model-based approach to dose selection in early pediatric development. Clin Pharmacol Ther 2010; 87: 294-302.
11. Paediatric European Network for Treatment of AIDS (PENTA). Pharmacokinetic study of once-daily versus twice-daily abacavir and lamivudine in HIV type-1-infected children aged 3-<36 months. Antivir Ther 2010; 15: 297-305.
12. Krekels EH, van Hasselt JG, Tibboel D, Danhof M, Knibbe CA. Systematic evaluation of the descriptive and predictive performance of paediatric morphine population models. Pharm Res 2011; 28: 797-811.
13. Hooker AC, Staatz CE, Karlsson MO. Conditional weighted residuals (CWRES): a model diagnostic for the FOCE method. Pharm Res 2007; 24: 2187-97.
14. Lindbom L, Ribbing J, Jonsson EN. Perl-speaks-NONMEM (PsN) - a Perl module for NONMEM related programming. Comput Methods Programs Biomed 2004; 75: 85-94.
15. Brendel K, Comets E, Laffont C, Laveille C, Mentré F. Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide. Pharm Res 2006; 23: 2036-49.
16. Comets E, Brendel K, Mentré F. Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the npde add-on package for R. Comput Methods Programs Biomed 2008; 90: 154-66.
17. Zhao W, Elie V, Baudouin V, Bensman A, André JL, Brochard K, Broux F, Cailliez M, Loirat C, Jacqz-Aigrain E. Population pharmacokinetics and Bayesian estimator of mycophenolic acid in children with idiopathic nephrotic syndrome. Br J Clin Pharmacol 2010; 69: 358-66.
18. Zhao W, Fakhoury M, Baudouin V, Maisin A, Deschênes G, Jacqz-Aigrain E. Limited sampling strategy for estimating individual exposure of tacrolimus in pediatric kidney transplant patients. Ther Drug Monit. doi: 10.1097/FTD.0b013e318235d067.
19. Jullien V, Tréluyer JM, Chappuy H, Dimet J, Rey E, Dupin N, Salmon D, Pons G, Urien S. Weight related differences in the pharmacokinetics of abacavir in HIV-infected patients. Br J Clin Pharmacol 2005; 59: 183-8.
20. Jullien V, Urien S, Chappuy H, Dimet J, Rey E, Pons G, Blanche S, Tréluyer JM. Abacavir pharmacokinetics in human immunodeficiency virus-infected children ranging in age from 1 month to 16 years: a population analysis. J Clin Pharmacol 2005; 45: 257-64.
21. Anderson BJ, Holford NH. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol 2008; 48: 303-32.
22. Björkman S. Prediction of cytochrome p450-mediated hepatic drug clearance in neonates, infants and children: how accurate are available scaling methods? Clin Pharmacokinet 2006; 45: 1-11.
23. Strassburg CP, Strassburg A, Kneip S, Barut A, Tukey RH, Rodeck B, Manns MP. Developmental aspects of human hepatic drug glucuronidation in young children and adults. Gut 2002; 50: 259-65.
24. Zhao W, Fakhoury M, Jacqz-Aigrain E. Developmental pharmacogenetics of immunosuppressants in pediatric organ transplantation. Ther Drug Monit 2010; 32: 688-99.
25. Knibbe CA, Krekels EH, van den Anker JN, DeJongh J, Santen GW, van Dijk M, Simons SH, van Lingen RA, Jacqz-Aigrain EM, Danhof M, Tibboel D. Morphine glucuronidation in preterm neonates, infants and children younger than 3 years. Clin Pharmacokinet 2009; 48: 371-85.
26. Bergshoeff A, Burger D, Verweij C, Farrelly L, Flynn J, Le Prevost M, Walker S, Novelli V, Lyall H, Khoo S, Gibb D, PENTA-13 Study Group. Plasma pharmacokinetics of once- versus twice-daily lamivudine and abacavir: simplification of combination treatment in HIV-1-infected children (PENTA-13). Antivir Ther 2005; 10: 239-46.
27. Allegaert K, Vanhaesebrouck S, Verbesselt R, van den Anker JN. In vivo glucuronidation activity of drugs in neonates: extensive interindividual variability despite their young age. Ther Drug Monit 2009; 31: 411-5.
28. van der Meer AF, Marcus MA, Touw DJ, Proost JH, Neef C. Optimal sampling strategy development methodology using maximum a posteriori bayesian estimation. Ther Drug Monit 2011; 33: 133-46.
29. Neely MN, Rakhmanina NY. Pharmacokinetic optimization of antiretroviral therapy in children and adolescents. Clin Pharmacokinet 2011; 50: 143-89.
30. Fabbiani M, Di Giambenedetto S, Bracciale L, Bacarelli A, Ragazzoni E, Cauda R, Navarra P, De Luca A. Pharmacokinetic variability of antiretroviral drugs and correlation with virological outcome: 2 years of experience in routine clinical practice. J Antimicrob Chemother 2009; 64: 109-17.
31. Grant PM, Zolopa AR. Optimal antiretroviral therapy: HIV-1 treatment strategies to avoid and overcome drug resistance. Curr Opin Investig Drugs 2010; 11: 901-10.